Evidence map›Paper›PMID 42676970›Full record

ReviewFrontiers in pharmacology2026

Linalool in cancer pharmacology: pharmacokinetic limitations and preclinical cytotoxic evidence for translational development.

Asad Abbas, Muhammad Bilal, Fatima Jafar, Ralf Weiskirchen, Adnan Amjad, Muhammad Khurram Afzal, Sawaira Bibi, Anza Saleem, Muhammad Israr, Aimen Mazhar and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Asad AbbasDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Muhammad BilalFaculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Fatima JafarDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Ralf WeiskirchenInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen, Germany.
Adnan AmjadDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Muhammad Khurram AfzalDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Sawaira BibiDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Anza SaleemMultan College of Nutritional Sciences, Multan Medical and Dental College, Multan, Pakistan.
Muhammad IsrarDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Aimen MazharDepartment of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan.
Bipindra PandeyDepartment of Pharmacy, Madan Bhandari Academy of Health Sciences, Hetauda, Bagmati, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer pharmacology increasingly evaluates plant-derived metabolites as lead compounds, but preclinical cytotoxicity should not be equated with clinical anticancer efficacy. Linalool, an acyclic monoterpene alcohol present in several aromatic plants and essential oils, has been investigated as an isolated compound and as a component of linalool-containing preparations. This critical narrative review evaluates pharmacokinetic evidence related to linalool, delivery considerations, the relevance of extraction methods, and preclinical cancer-model findings, with explicit separation of computational predictions,

Indexed as

apoptosisbioavailabilitycancer cell linescytotoxicityevidence appraisalextraction methodslinaloolpharmacokinetics

Identifiers

PMID42676970
PMCPMC13527556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.